Research map: Highly Novel Drugs Outperformed Less Novel Drugs In Gross And Net Revenues In The US, Driven Primarily By Utilization, 2013–19

Back to the article

Papers in this map

  1. ChEMBL: a large-scale bioactivity database for drug discovery · Anna Gaulton · 2011 · 4585 citations · Cited by this paper
  2. The Extent Of Gender/Sex Variables Included In Clinical Algorithms Across Medical Specialties · 2026 · Related
  3. Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry · Daron Acemoğlu · 2004 · 982 citations · Cited by this paper
  4. Participatory Systems Science To Identify Local Adaptation Strategies For Extreme Heat In King County, Washington · 2026 · Related
  5. Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems · Tsvetelina H. Baryakova · 2023 · 489 citations · Cited by this paper
  6. Health Insurance As Climate Adaptation: A Practical Framework · 2026 · Related
  7. Metabolic changes in aging humans: current evidence and therapeutic strategies · Allyson K. Palmer · 2022 · 338 citations · Cited by this paper
  8. The Uneven Distribution Of Patient Portal Messages Across Patients And Physicians · 2026 · Related
  9. Market size and pharmaceutical innovation · Pierre Dubois · 2015 · 258 citations · Cited by this paper
  10. Who Pays When Temperatures Soar? · 2026 · Related
  11. Market size and innovation: Effects of Medicare Part D on pharmaceutical research and development · Margaret E. Blume‐Kohout · 2012 · 229 citations · Cited by this paper
  12. Errata · 2026 · Related
  13. Market incentives and pharmaceutical innovation · Wesley Yin · 2008 · 194 citations · Cited by this paper
  14. Rhode Island’s Affordability Standards Led To Substantial Reductions In Hospital Staffing And Labor Costs By 2022 · 2026 · Related
  15. National Health Spending In 2014: Faster Growth Driven By Coverage Expansion And Prescription Drug Spending · Anne B. Martin · 2015 · 177 citations · Cited by this paper
  16. Cold-Related Illness In An Era Of Extreme Climate Events: US Trends, 1998–2022 · 2026 · Related
  17. Missing Novelty in Drug Development · Joshua Krieger · 2021 · 103 citations · Cited by this paper
  18. Health Care Workers In A Storm’s Path · 2026 · Related
  19. Variations in tissue selectivity amongst insulin secretagogues: a systematic review · Ahmed Sayed Abdel-Moneim · 2011 · 87 citations · Cited by this paper
  20. The South Had The Lowest Rates Of Hospice And Palliative Medicine–Certified Providers In The US, 2024 · 2026 · Related
  21. Pharmacy Benefit Managers · T. Joseph Mattingly · 2023 · 59 citations · Cited by this paper
  22. Drug Regulation and Pricing — Can Regulators Influence Affordability? · Hans‐Georg Eichler · 2016 · 49 citations · Cited by this paper
  23. Added benefit and revenues of oncology drugs approved by the European Medicines Agency between 1995 and 2020: retrospective cohort study · Francine Brinkhuis · 2024 · 42 citations · Cited by this paper
  24. A Markov‐perfect equilibrium model of the impacts of price controls on the performance of the pharmaceutical industry · Darren Filson · 2012 · 40 citations · Cited by this paper
  25. Insurance Design and Pharmaceutical Innovation · Leila Agha · 2022 · 38 citations · Cited by this paper
  26. An evaluation of pitavastatin for the treatment of hypercholesterolemia · Paul S. Chan · 2018 · 26 citations · Cited by this paper
  27. `Me-Too' Innovation in Pharmaceutical Markets · Anupam Bapu Jena · 2009 · 23 citations · Cited by this paper
  28. Does consumer demand pull scientifically novel drug innovation? · David Dranove · 2022 · 20 citations · Cited by this paper
  29. Association of Branded Prescription Drug Rebate Size and Patient Out-of-Pocket Costs in a Nationally Representative Sample, 2007-2018 · Kai Yeung · 2021 · 12 citations · Cited by this paper
  30. Medicare Part D: Patients Bear The Cost Of ‘Me Too’ Brand-Name Drugs · Nicole Gastala · 2016 · 11 citations · Cited by this paper
  31. Small-Molecule Drugs Offer Comparable Health Benefits To Biologics At Lower Costs · Katherine A. Clifford · 2024 · 9 citations · Cited by this paper
  32. Rising Drug Costs Drives the Growth of Pharmacy Benefit Managers Exclusion Lists: Are Exclusion Decisions Value‐Based? · Joshua Cohen · 2017 · 6 citations · Cited by this paper
  33. The ‘Invisible Hand’ Doesn't Work for Prescription Drugs · David S. Guzick · 2022 · 2 citations · Cited by this paper
  34. Untitled · Cited by this paper

Source: OpenAlex (CC0)